Fundz

Watching Vaxcyte, Inc.? See every signal: funding, hires, M&A, contracts, sentiment.

Book a demoChoose your plan
Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly. See plans and pricing.See plans →
Back to SEC Filings
Executive ChangeItem 5.02 · 8-KLOW RiskNeutral

Vaxcyte, Inc.

Filed: Jul 13, 2026CIK: 0001649094
View on SEC.gov

AI Executive Summary

AI-powered analysis of 8-K filing content

Heath Lukatch retired from Vaxcyte's Board of Directors effective July 16, 2026, after over eight years of service. John Mar was appointed to the Board following a recommendation from the Nominating and Corporate Governance Committee.

Key Takeaways

Heath Lukatch's departure is amicable with no disagreements cited, indicating a planned transition rather than a conflict-driven exit

John Mar's appointment suggests the Board is refreshing its composition with new perspectives while maintaining continuity

1 more takeaway

Filing Overview

Form Type8-K
Filing DateJul 13, 2026
Item5.02
CategoryExecutive Change
CIK0001649094
Accession #pcvx-20260713
Risk LevelLOW
SentimentNeutral
Signalinformational
Topics
board changeleadership transition

What This Means

A senior executive (CEO, CFO, etc.) has joined, departed, or changed roles. Leadership changes can significantly impact strategy.
View Full Filing on SEC.govBrowse More Filings

Vaxcyte, Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.